Evidence map›Paper›PMID 34082765›Full record

ReviewVirology journal2021

Functional cure for chronic hepatitis B: accessibility, durability, and prognosis.

Aixin Song, Xiao Lin, Xinyue Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Short-chain Fatty Acids and Bile Acids Signaling in Chronic Hepatitis B.Journal of clinical and translational hepatology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aixin SongFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xiao LinFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xinyue ChenFirst Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China. chenxydoc@ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral treatment in terms of drug withdrawal safety and improvements in prognosis. However, the overall rate of HBsAg clearance is low and differs based on treatment method and course. The recent application of combined and extended treatment strategies have improved the HBsAg clearance rate, and several patients achieved HBsAg clearance in clinical treatment. In addition, the durability of and clinical outcomes after HBsAg clearance have become the focus of both researchers and clinicians. This article reviews HBsAg clearance in terms of accessibility, durability, improvements in prognosis and relevant advances.

Indexed as

Antiviral AgentsHepatitis B, ChronicHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansPrognosisTreatment OutcomeAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensHBsAg clearanceHepatitis B virusPrognosis

Identifiers

PMID34082765
PMCPMC8176700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.